



Interleukin-17 patent granted in Europe

Issuance of a European patent covering the use of IL-17A antagonists for the treatment of cancer

Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapies for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. *"The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL-17 programs"*, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. *"Intellectual property is a key asset in OREGA's target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage."*

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. With a specific focus on tumor microenvironment, OREGA Biotech's target discovery program aims at discovering and validating novel clinically-relevant oncology targets.

Incepted in 2010, OREGA Biotech is based on the research conducted by its academic co-founders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. OREGA's business strategy is to bring its R&D programs up to preclinical proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. Funded by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative, the company is managed by Jeremy Bastid, COO and Gilles Alberici, co-founder and CEO.

Contact

Jeremy Bastid, Chief Operating Officer
Tel.: +33 (0)4 37 49 87 20
jeremy.bastid@orega-biotech.com

For more information: www.orega-biotech.com